A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib, a targeted cancer treatment, can...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 11/Dec 15:28
Unexpected discovery revives abandoned breast cancer treatment
A new study led by Lund University in Sweden has solved a years-old mystery: which patients with aggressive breast cancer are helped by a targeted cancer treatment that had been under development but was shelved. The study is important since it brings hope that the development of the drug can continue and that it will [...]
Articles similaires
10 Most Interesting Science News of 2024
thecekodok.com - 12/Dec 22:33
The year 2024 saw interesting developments in the science of cancer treatment, vaccines and genetic discoveries. Two Nobel Prize winners were involved...
Break it Down: Radiopharm Theranostics progresses along path to help heal HER-2 cancer
stockhead.com.au - 20/Dec 01:04
Sarah Hughan details Radiopharm Theranostics' first in-human study approval for the treatment of breast and gastric cancers. ...
Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class β-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)
drugs.com - 19/Dec 01:12
TARRYTOWN, N.Y., December 19, 2024 – Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and...
Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class β-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)
drugs.com - 19/Dec 01:12
TARRYTOWN, N.Y., December 19, 2024 – Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and...
A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth
oncologynews.com.au - 16/Dec 13:18
A new study led by UCLA Health Jonsson Comprehensive Cancer Center (USA) investigators offers new evidence that dietary changes may help reduce...
Hair growth drug safe at low doses for breast cancer patients
oncologynews.com.au - 19/Dec 17:32
Hair loss during chemotherapy can cause enough distress for some women to lose self-confidence, which experts say may discourage them from seeking...
Hair growth drug safe at low doses for breast cancer patients
oncologynews.com.au - 19/Dec 17:32
Hair loss during chemotherapy can cause enough distress for some women to lose self-confidence, which experts say may discourage them from seeking...
Assessing the impact of gozetotide in PSMA-positive prostate cancer
news.medical.net - 21/Dec 03:12
Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes...
SABCS: Chest Wall Irradiation Does Not Impact Survival in Breast Cancer
drugs.com - 16/Dec 16:12
MONDAY, Dec. 16, 2024 -- For patients with intermediate-risk breast cancer, chest wall irradiation (CWI) after mastectomy does not influence 10-year...
Les derniers communiqués
-
Aucun élément